Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 104Colorectal Neoplasms 63Stomach Neoplasms 49Rectal Neoplasms 42Colonic Neoplasms 24Neoplasm Metastasis 21Nasopharyngeal Carcinoma 19Triple Negative Breast Neoplasms 18Pancreatic Neoplasms 14Parkinson Disease 4, Autosomal Dominant Lewy Body 12Neoplasms 12Gallbladder Neoplasms 7Cholangiocarcinoma 7Adenocarcinoma 6Esophageal Neoplasms 5Biliary Tract Neoplasms 5Adenocarcinoma Of Esophagus 5Esophageal Squamous Cell Carcinoma 4Neuroendocrine Tumors 3Gastrointestinal Neoplasms 3Digestive System Neoplasms 3Bile Duct Neoplasms 3Recurrence 2Pathologic Complete Response 2Liver Neoplasms 2Intestinal Neoplasms 2Hand-Foot Syndrome 2HER2-positive Advanced Breast Cancer 2HER2 Positive Metastatic Breast Cancer 2Drug-Related Side Effects and Adverse Reactions 2

Interventions

Oxaliplatin 1Leucovorin 1Irinotecan 1Fluorouracil 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Cirrhosis, Familial, with Pulmonary Hypertension × Capecitabine × Clear all
NCT07328919 2026-01-09

Efficacy and Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patients With Advanced Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusions/Rearrangements or Mutations

TransThera Sciences (Nanjing), Inc.

Phase 3 Not yet recruiting
138 enrolled
Gastrointestinal

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡